On this page

Econazole Nitrate

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Econazole Nitrate
Generic name
Econazole Nitrate
Dosage form
Cream
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
11
Packages
21
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Econazole Nitrate 10 mg/g 1442585 —

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
32

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Azole Antifungal [EPC] EPC All 44 members
Azoles [CS] CS All 44 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
076479
Application type
ANDA · Abbreviated New Drug Application
Approval date
June 23, 2004
Sponsor
PADAGIS ISRAEL
Products on application
1
Submissions recorded
1
Products approved under application 076479.
Product Trade name Form Strength Ingredient Status TE Flags
076479-001 ECONAZOLE NITRATE CREAM ECONAZOLE NITRATE Prescription AB RS

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 076479.
Type No. Action Status Date Review
Original application 1 Approved June 23, 2004 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260622). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260622 HUMAN PRESCRIPTION DRUG · 20260512 HUMAN PRESCRIPTION DRUG · 20260410 HUMAN PRESCRIPTION DRUG · 20250129

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Econazole nitrate cream is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum , in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Sufficient econazole nitrate cream, 1%, should be applied to cover affected areas once daily in patients with tinea pedis, tinea cruris, tinea corporis, and tinea versicolor, and twice daily (morning and evening) in patients with cutaneous candidiasis. Early relief of symptoms is experienced by the majority of patients and clinical improvement may be seen fairly soon after treatment is begun; however, candidal infections and tinea cruris and corporis should be treated for two weeks and tinea pedis for one month in order to reduce the possibility of recurrence. If a patient shows no clinical improvement after the treatment period, the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Econazole Nitrate Cream is contraindicated in individuals who have shown hypersensitivity to any of its ingredients.

WARNINGS Econazole Nitrate Cream is not for ophthalmic use.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS During clinical trials, approximately 3% of patients treated with econazole nitrate cream, 1 % reported side effects thought possibly to be due to the drug, consisting mainly of burning, itching, stinging, and erythema. One case of pruritic rash has also been reported.

Drug Interactions

openFDA Drug Labeling

Drug Interactions Warfarin Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulation effect. Most cases reported product application with use under occlusion, genital application, or application to large body surface area which may increase the systemic absorption of econazole nitrate. Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.

Description

openFDA Drug Labeling

DESCRIPTION Econazole nitrate cream contains the antifungal agent, econazole nitrate USP 1%, in a water-miscible base consisting of benzoic acid, butylated hydroxytoluene, mineral oil, oleoyl polyoxylglycerides PEG-6-32 stearate/glycol stearate and purified water. The white to off-white soft cream is for topical use only. Chemically, econazole nitrate is 1-[2-{(4-chloro-phenyl) methoxy}-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole mononitrate. Its structure is as follows: Chemical Structure

OVERDOSAGE Overdosage of econazole nitrate in humans has not been reported to date. In mice, rats, guinea pigs and dogs, the oral LD 50 values were found to be 462, 668, 272, and >160 mg/kg, respectively.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Econazole Nitrate Cream, 1% contains econazole nitrate USP. The white to off-white homogenous cream is available as follows: 15 g aluminum tube NDC 59651-945-14 30 g aluminum tube NDC 59651-945-30 85 g aluminum tube NDC 59651-945-85 Store econazole nitrate cream below 30°C (86°F). To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch for voluntary reporting of adverse reactions. Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Manufactured by: Aurobindo Pharma Limited Hyderabad-500 032, India Revised: 04/2026

Adverse event reports

Source: openFDA FAERS
920
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: ECONAZOLE NITRATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
59651-945-14 59651-945 Aurobindo Pharma Limited 1 TUBE in 1 CARTON (59651-945-14) / 15 g in 1 TUBE March 13, 2026
59651-945-30 59651-945 Aurobindo Pharma Limited 1 TUBE in 1 CARTON (59651-945-30) / 30 g in 1 TUBE March 13, 2026
59651-945-85 59651-945 Aurobindo Pharma Limited 1 TUBE in 1 CARTON (59651-945-85) / 85 g in 1 TUBE March 13, 2026
63629-8645-1 63629-8645 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8645-1) / 15 g in 1 TUBE December 21, 2006
63629-8646-1 63629-8646 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8646-1) / 30 g in 1 TUBE November 10, 2006
63629-8647-1 63629-8647 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8647-1) / 85 g in 1 TUBE August 8, 2006
72162-1410-2 72162-1410 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1410-2) / 85 g in 1 TUBE August 17, 2023
72162-1410-3 72162-1410 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1410-3) / 30 g in 1 TUBE August 17, 2023
72162-1410-4 72162-1410 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1410-4) / 15 g in 1 TUBE August 17, 2023
21922-111-04 21922-111 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-111-04) / 15 g in 1 TUBE July 1, 2026
21922-111-05 21922-111 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-111-05) / 30 g in 1 TUBE July 1, 2026
21922-111-15 21922-111 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-111-15) / 85 g in 1 TUBE July 1, 2026
45802-466-11 45802-466 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-466-11) / 30 g in 1 TUBE November 10, 2006
45802-466-35 45802-466 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-466-35) / 15 g in 1 TUBE December 21, 2006
45802-466-53 45802-466 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-466-53) / 85 g in 1 TUBE August 8, 2006
68788-8170-3 68788-8170 Preferred Pharmaceuticals Inc. 1 TUBE in 1 CARTON (68788-8170-3) / 30 g in 1 TUBE April 11, 2022
68788-8174-1 68788-8174 Preferred Pharmaceuticals Inc. 1 TUBE in 1 CARTON (68788-8174-1) / 15 g in 1 TUBE April 27, 2022
68788-8884-3 68788-8884 Preferred Pharmaceuticals Inc. 1 TUBE in 1 CARTON (68788-8884-3) / 30 g in 1 TUBE June 2, 2025
51672-1303-1 51672-1303 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1303-1) / 15 g in 1 TUBE November 26, 2002
51672-1303-2 51672-1303 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1303-2) / 30 g in 1 TUBE November 26, 2002
51672-1303-8 51672-1303 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1303-8) / 85 g in 1 TUBE November 26, 2002
59651-945 59651-945 Aurobindo Pharma Limited — March 13, 2026
63629-8645 63629-8645 Bryant Ranch Prepack — August 8, 2006
63629-8646 63629-8646 Bryant Ranch Prepack — August 8, 2006
63629-8647 63629-8647 Bryant Ranch Prepack — August 8, 2006
72162-1410 72162-1410 Bryant Ranch Prepack — August 8, 2006
21922-111 21922-111 Encube Ethicals, Inc. — July 1, 2026
45802-466 45802-466 Padagis Israel Pharmaceuticals Ltd — August 8, 2006
68788-8170 68788-8170 Preferred Pharmaceuticals Inc. — April 11, 2022
68788-8174 68788-8174 Preferred Pharmaceuticals Inc. — April 27, 2022
68788-8884 68788-8884 Preferred Pharmaceuticals Inc. — August 8, 2006
51672-1303 51672-1303 Sun Pharmaceutical Industries, Inc. — November 26, 2002

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.